Dana-Farber researchers present findings in more than 70 research studies at ASCO

Boston – Dana-Farber Cancer Institute researchers are presenting more than 70 research studies at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31st- June 4th. ASCO is the world’s largest clinical cancer research meeting, attracting more than 30,000 oncology professionals from around the world. The latest cancer research…

Announcing updates to PCR-EAPCI Textbook

A new update to the PCR-EAPCI Textbook for EuroPCR 2019 features new chapters on invasive physiological assessment of coronary disease, and the role of imaging in CTO intervention. It includes updates to 15 chapters including bifurcation lesions and left main coronary artery disease. Additional updates and new chapters are planned to coincide with the ESC…

PCR statement on evolving indications for transcatheter aortic valve implantation

Paris, France, 21 May 2019. Severe symptomatic aortic stenosis, a degenerative disease-causing calcification and immobility of the aortic valve leaflets leading to left ventricular outflow obstruction, is the most common valve lesion leading to intervention in Europe and the USA. Symptoms include heart failure, syncope and angina, and have a dismal prognosis if left untreated.…

A PCR statement on behalf of PCR and the EAPCI

Paris, France, 21 May 2019. Heart failure is a common cardiovascular disorder with ominous prognosis despite significant therapeutic advances. Mitral regurgitation (MR, leaking of the mitral valve within the heart) affects at least 50% of patients with heart failure and is independently associated with worse prognosis. Timely diagnosis is essential, and management is complex, requiring…